Yahoo Search Búsqueda en la Web

Entrar

Resultado de búsqueda

  1. www.gilead.com › news-and-press › press-roomGilead Provides Update on Phase 3 TROPiCS-04 Study

    Hace 4 días · FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the confirmatory Phase 3 TROPiCS-04 study in locally advanced or metastatic urothelial cancer (mUC). The TROPiCS-04 study evaluated Trodelvy ® (sacituzumab govitecan-hziy; SG) vs. single-agent chemotherapy (treatment of physicians’ choice, TPC) in patients with mUC who have ...

    • Careers at Gilead

      Equal Opportunities . As an equal opportunity employer,...

    • Medicines

      Gilead is committed to helping improve the lives of people...

    • U.S. Locations

      The Gilead office in Miami, Fla., is home to members of the...

    • Contact Us

      Find contact information for Gilead Sciences, Inc. Medicine...

    • Company Statements

      Gilead Statement on Uganda's Anti-Homosexuality Act....

    • Events

      At Gilead, we promise to treat your data with respect. You...

  2. Videos

    Ver todo

  3. es.marketscreener.com › cotizacion › accionLa unidad de Gilead Sciences afirma que Tecartus mejora la ...

    Hace 18 horas · Gilead Sciences, Inc. está especializada en el desarrollo, la fabricación y la comercialización de productos terapéuticos. Las ventas netas se desglosan por fuentes de ingresos como sigue - venta de medicamentos (98,9%): para el tratamiento del VIH (63% de las ventas netas), COVID-19 (20,4%), virus de la hepatitis C (6,6%), virus de la hepatitis B (3,6%) y otros (6,4%; principalmente ...

  4. es.investing.com › news › company-newsBMO mantiene el objetivo sobre las acciones de Gilead a pesar del...

    Hace 18 horas · Mientras Gilead Sciences sigue avanzando por la vía regulatoria, la reiteración del precio objetivo por parte de BMO Capital Markets sugiere confianza en las perspectivas generales de la compañía.

  5. www.businesswire.com › news › homeGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus...

    Hace 2 días · Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people.

  6. investors.gilead.com › news › news-detailsGilead Sciences, Inc. - Gilead and Arcus Announce Etrumadenant...

    Hace 1 día · – In Cohort B of the ARC-9 mCRC Study, Etrumadenant Plus Zimberelimab, FOLFOX Chemotherapy and Bevacizumab Significantly Reduced the Risk of Death by 63% and Risk of Disease Progression by 73% Compared to Regorafenib in a Phase 1b/2 Trial – – Results will be Presented Today During an Oral Session at the ASCO Annual Meeting – Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences ...

  7. investors.gilead.com › news › news-detailsGilead Provides Update on Phase 3 TROPiCS-04 Study

    Hace 4 días · Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the confirmatory Phase 3 TROPiCS-04 study in locally advanced or metastatic urothelial cancer (mUC).

  8. es.marketscreener.com › cotizacion › accionGilead Sciences, Inc. proporciona información actualizada sobre...

    Hace 4 días · 30 de mayo 2024 a las 22:45. Comparte. Gilead Sciences, Inc. anunció los resultados de primera línea del estudio confirmatorio de fase 3 TROPiCS-04 en cáncer urotelial localmente avanzado o metastásico (mUC). El estudio TROPiCS-04 evaluó Trodelvy® (sacituzumab govitecan-hziy; SG) frente a quimioterapia de agente único ...